PMA device
Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna Test
Qiagen Gaithersburg, Inc. · Kit, Dna Detection, Human Papillomavirus (MAQ, Class III) · First FDA decision Apr 14, 2014, newest Apr 14, 2014Cervical cancer and HPV
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
1
Naming "Digene HC2 High"
MAUDE reports
0
Brand "Digene HC2 High", since 2015
PubMed studies
11
Mentioning "Digene HC2 High"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Digene HC2 High Risk Hpv Dna Test and Digene HC2 Hpv Dna Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P890064-S029 · Decided Apr 14, 2014 · 242 days after receipt · Normal 180 Day Track No User Fee
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening for Cervical Cancer with Human Papillomavirus (HPV) TestingNational analysisReview closedCAG-00442NUpdated Sep 22, 2026
- Screening for Cervical Cancer with Human Papillomavirus (HPV)National determinationOn the books210.2.1Updated Jun 17, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Digene HC2 High", any status and sponsor, newest update first.
Becton, Dickinson and CompanyPublic (BDX)
NCT01234480 · 5,859 participants · Start Sep 2010 · Primary completion Mar 2012
Device: BD SurePath Plus Pap test; BD SurePath Pap test and 1 more · For: Uterine Cervical Neoplasms; Uterine Cervical Cancer; Neoplasms, Squamous Cell and 4 more
Sites: Seattle, Washington
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Digene HC2 High", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MAQ
310 reports: 306 malfunction, 3 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Digene HC2 High"[tiab]. The summary above synthesizes these.
- Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
Nakamura M, Nakade K, Orisaka S, et al. · Am J Clin Pathol · 2019Comparative Study, Evaluation Study
- Oral Human Papillomavirus Infection among Smokeless Tobacco-using Tribal Women in Mysuru, India.
Ravi K, Kaur T, Khan AS, et al. · Indian J Community Med · 2023
- High-risk HPV prevalence in the Czech cervical cancer screening population: a comparison of clinician-collected and self-collected sampling.
Jaworek H, Bouska O, Kourilova P, et al. · Eur J Public Health · 2025Comparative Study, Multicenter Study
- Development and characterization of the cobas human papillomavirus test.
Rao A, Young S, Erlich H, et al. · J Clin Microbiol · 2013Evaluation Study, Research Support, Non-U.S. Gov't
- Evaluation of CellSolutions BestPrep® automated thin-layer liquid-based cytology Papanicolaou slide preparation and BestCyte® cell sorter imaging system.
Delga A, Goffin F, Kridelka F, et al. · Acta Cytol · 2014Research Support, Non-U.S. Gov't
- Simultaneous amplification and identification of 25 human papillomavirus types with Templex technology.
Han J, Swan DC, Smith SJ, et al. · J Clin Microbiol · 2006Research Support, N.I.H., Extramural
- A comparison of different human papillomavirus tests in PreservCyt versus SurePath in a referral population-PREDICTORS 4.
Cuzick J, Ahmad AS, Austin J, et al. · J Clin Virol · 2016Comparative Study, Evaluation Study
- High-risk HPV nucleic acid detection kit-the careHPV test -a new detection method for screening.
Ying H, Jing F, Fanghui Z, et al. · Sci Rep · 2014Evaluation Study
- Clinical laboratory experience with cervista HPV HR as a function of cytological classification: comparison with retrospective digene HC2 high-risk HPV DNA test data.
Du Chateau BK, Schroeder ER, Munson E · J Clin Microbiol · 2013Comparative Study, Evaluation Study
- Role of Training Paramedical Staff for Cervical Cancer Screening via Human Papillomavirus Self-Sampling in Remote Mountainous Regions: A Pilot Feasibility Study.
Singh N, Raj Jalagam V, Somagattu S, et al. · Cureus · 2026
- Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A, Sandri MT, Sideri M, et al. · J Clin Virol · 2013Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code MAQ.
- cobas HPVRoche Molecular Systems, Inc. · PMA 2026
- BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)Becton, Dickinson and Company · PMA 2026
- Digene Hybrid Capture 2 (HC2) Hpv Dna TestsQiagen Gaithersburg, Inc. · PMA 2015
- Alinity m HR HPVAbbott Molecular, Inc. · PMA 2026
- Cervista Hpv Hr and Genfind KitHologic, Inc. · PMA 2014
- Cervista Hpv 16/18Hologic, Inc. · PMA 2014
- Onclarity HPV AssayBecton, Dickinson and Company · PMA 2025
- Digene Hybrid CAPTURE2Qiagen Gaithersburg, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.